Comparative Pharmacology
Head-to-head clinical analysis: MALARONE versus PYRIMETHAMINE SULFADOXINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MALARONE versus PYRIMETHAMINE SULFADOXINE.
MALARONE vs Pyrimethamine-Sulfadoxine
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Atovaquone is a selective inhibitor of the mitochondrial electron transport chain at the cytochrome bc1 complex (Complex III), disrupting pyrimidine synthesis and ATP generation in Plasmodium species. Proguanil, via its metabolite cycloguanil, inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis. Synergistic activity against erythrocytic and exoerythrocytic stages.
Pyrimethamine inhibits dihydrofolate reductase, blocking tetrahydrofolate synthesis. Sulfadoxine inhibits dihydropteroate synthase, blocking folate synthesis. Sequential blockade of folate metabolism.
For malaria treatment: 4 tablets (each containing atovaquone 250 mg/proguanil 100 mg) orally once daily for 3 consecutive days. For malaria prophylaxis: 1 tablet (atovaquone 250 mg/proguanil 100 mg) orally once daily starting 1-2 days before travel, continued during travel and for 7 days after leaving endemic area.
Pyrimethamine 25 mg plus sulfadoxine 500 mg per tablet; typical adult dose for acute uncomplicated malaria is 3 tablets (pyrimethamine 75 mg, sulfadoxine 1500 mg) orally as a single dose. For toxoplasmosis in immunocompromised patients: loading dose pyrimethamine 200 mg orally once, then pyrimethamine 50-75 mg orally once daily plus sulfadoxine 1000-1500 mg orally once daily (dosing based on sulfadoxine component) for 4-6 weeks, then reduce to half.
None Documented
None Documented
Atovaquone: 50-70 hours (mean ~60 h); proguanil: 12-21 hours (mean ~16 h); cycloguanil: 10-16 hours. Long half-life of atovaquone allows single-dose treatment, but may delay parasite clearance.
Pyrimethamine: ~80-120 hours; Sulfadoxine: ~100-200 hours. Long half-lives allow single-dose therapy for malaria.
Atovaquone: 94% excreted unchanged in feces via biliary elimination, 6% in urine. Proguanil: 40-60% excreted unchanged in urine; cycloguanil (active metabolite) and proguanil metabolites also cleared renally.
Renal: ~60% unchanged sulfadoxine, ~5% unchanged pyrimethamine; fecal: ~10% pyrimethamine. Biliary excretion minimal.
Category C
Category C
Antimalarial
Antimalarial